OPHT Ophthotech

Ophthotech Corporation to Report First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018

NEW YORK--(BUSINESS WIRE)--

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

To participate in this conference call, dial 800-239-9838 (USA) or 323-794-2551 (International), passcode 2075643. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Ophthotech website at: www.ophthotech.com. A replay will be available approximately two hours following the live call for two weeks. The replay number is 888-203-1112 (USA Toll Free), passcode 2075643.

About Ophthotech Corporation

Ophthotech is a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. For more information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Ophthotech's views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so.

OPHT-G

EN
01/05/2018

Underlying

OPHTOphthotech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ophthotech

Free Trial
OPHT OPHTHOTECH

OPHTHOTECH CORP. sees a downgrade to Negative on account of less funda...

The independent financial analyst theScreener just lowered the general evaluation of OPHTHOTECH CORP. (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date February 1, 2019, the closing price was USD 1.25 and its target pr...

02/02/19 February 2, 2019 6 EN
 PRESS RELEASE
Free
OPHT OPHTHOTECH

Ophthotech Reports First Quarter 2018 Financial and Operating Results

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the first quarter ended March 31, 2018 and provided a business update. “We continue to build on our Zimura program with on-going clinical trials in wet age related macular degeneration (AMD) with patient recruitment completed and topline data expected by the end of 2018, in geographic atrophy secondary to dry AMD where recruitment is on-track for topline data in the second half of 2019 and in autosomal recessiv...

May 9, 2018 1 EN
 PRESS RELEASE
Free
OPHT OPHTHOTECH

Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Tria...

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ: OPHT) today announced the completion of patient enrollment in its Phase 2a clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). Zimura is administered in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor (anti-VEGF) agent, in treatment naïve patients with wet AMD. A total of 64 patients have been enrolled into this dose-ranging, open-label, ...

May 1, 2018 1 EN
 PRESS RELEASE
Free
OPHT OPHTHOTECH

Ophthotech Corporation to Report First Quarter 2018 Financial Results ...

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2018 financial and operating results on Wednesday, May 9, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update. To participate in this conference call, dial 800-239-9838 (USA) or 323-794-2551 (International), passcode 2075643. A live, listen-only ...

May 1, 2018 1 EN
 PRESS RELEASE
Free
OPHT OPHTHOTECH

Ophthotech to Present at the Cowen and Company 38th Annual Health Care...

NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 9:20 a.m. Eastern Time. Investors and the general public are invited to listen to a live webcast of the presentation on the Events & Presentations section on the Ophthotech website at www.ophthotech.com. An archived replay of the webcast will be availa...

March 6, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch